Research programme: migraine therapy - Orexo

Drug Profile

Research programme: migraine therapy - Orexo

Alternative Names: OX 40; OX641

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator PharmaKodex
  • Developer Orexo
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes - Migraine

Highest Development Phases

  • Discontinued Migraine

Most Recent Events

  • 06 Mar 2012 Discontinued - Preclinical for Migraine in Sweden (PO)
  • 21 Jul 2009 Preclinical development is ongoing in Sweden
  • 21 Jul 2009 OX 641 is available for licensing worldwide (http://www.orexo.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top